Clinical trials: Refractory Chronic Cough
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
Researchers in this study want to learn about the safety of drug BAY1817080 at different doses and the resulting blood levels of the study drug in Japanese healthy adult male participants.
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04265781
- Testing
- BAY1817080
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bayer
Endometriosis Related Pain, Overactive Bladder
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
Researchers are looking for a new way to treat people suffering either from a condition where the bladder is unable to hold urine normally (overactive bladder), or a condition in which tissue similar to the tissue that normally…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04487431
- Testing
- BAY1817080, [14C]BAY1817080
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04454424
- Testing
- BAY1817080, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Bayer
Chronic Refractory Cough
A Comprehensive Evaluation of the Impact of ATP on Laryngeal Symptoms, Hypersensitivity and Function
OBJECTIVES To deliver a comprehensive model of laryngeal assessment, evaluating both the sensory and motor components of upper airway control and to relate this to symptom disturbance.
- Trial name
- MISP COUGH (NCT05570981)
- Testing
- Laryngeal sensitivity testing
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Bispebjerg Hospital
Refractory and/or Unexplained Chronic Cough
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC).
- Trial name
- PAGANINI (NCT04562155)
- Testing
- BAY1817080
- Where
- 99 sites in United States, Argentina and 17 more
- Volunteers
- 310 people
- Sponsor
- Bayer
Chronic Refractory Cough
A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough
The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.
- Trial name
- NCT02993822
- Testing
- Orvepitant Maleate
- Where
- 66 sites in United States, Canada and 1 more
- Volunteers
- 315 people
- Sponsor
- Nerre Therapeutics Ltd.
Refractory Chronic Cough
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- SOOTHE (NCT04678206)
- Testing
- BLU-5937
- Where
- 116 sites in United States, Canada and 5 more
- Volunteers
- 310 people
- Sponsor
- Bellus Health Inc. - a GSK company
Chronic Refractory Cough
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
- Trial name
- RELIEF (NCT03979638)
- Testing
- BLU-5937
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Bellus Health Inc. - a GSK company
Refractory Chronic Cough
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
- Trial name
- NCT03282591
- Testing
- 5 mg Serlopitant Tablets
- Where
- 39 sites in United States, United Kingdom
- Volunteers
- 185 people
- Sponsor
- Vyne Therapeutics Inc.
Refractory Chronic Cough
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
The primary objective of this double-blind crossover study is to assess the effect of single doses of 50 mg and 300 mg gefapixant (AF-219/MK-7264) on cough reflex sensitivity to capsaicin in both healthy participants and…
- Trial name
- NCT02397460
- Testing
- Gefapixant
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory Chronic Cough
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
A randomized, double-blind, placebo-controlled, crossover, dose escalation study to assess the efficacy and tolerability of gefapixant (AF-219; MK-7264) in participants with refractory chronic cough.
- Trial name
- NCT02349425
- Testing
- Gefapixant
- Volunteers
- 59 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory Chronic Cough
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
This study is designed to evaluate the efficacy of three dose regimens of gefapixant ([MK-7264] 7.5 mg, 20 mg, and 50 mg) relative to placebo in reducing awake objective cough frequency.
- Trial name
- NCT02612610
- Testing
- Gefapixant
- Volunteers
- 253 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory Chronic Cough
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
- Trial name
- NCT02612623
- Testing
- Gefapixant
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory Chronic Cough
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
The primary objective of this study was to assess the effect of a single dose of gefapixant 100 mg on cough reflex sensitivity to various challenge agents (capsaicin, citric acid, adenosine triphosphate [ATP], and distilled…
- Trial name
- NCT02476890
- Testing
- Gefapixant 100 mg
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Refractory Chronic Cough
Indomethacin for Refractory Chronic Cough
Chronic cough is a common complain of patients in respiratory clinic and its global prevalence was up to 9.6%. Persistent cough of unexplained origin is a significant health issue that occurs in up to 5% to 10% of patients…
- Trial name
- NCT03662269
- Testing
- indomethacin, Omeprazole
- Where
- China
- Volunteers
- 84 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Refractory Chronic Cough
Treatment of Refractory Chronic Cough With PA101
This is a double-blind, randomized, placebo-controlled, 2-period crossover, 2-cohort study in adult patients with refractory chronic cough.
- Trial name
- NCT02412020
- Testing
- PA101
- Where
- 7 sites in Netherlands, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Patara Pharma
Chronic Refractory Cough
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic…
- Trial name
- NCT01703923
- Testing
- FP01
- Where
- 8 sites in United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Avalo Therapeutics, Inc.